CNS aspergillosis: Recognition, diagnosis and management

CNS Drugs

Volumn 21, Issue 8, 2007, Pages 659-676

  Ruhnke, Markus ^a,b   Kofla, Grzegorz ^a   Otto, Kirsten ^a   Schwartz, Stefan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CASPOFUNGIN; CORTICOSTEROID; FLUCONAZOLE; FLUCYTOSINE; GAMMA INTERFERON; ITRACONAZOLE; MICAFUNGIN; PHENYTOIN; POSACONAZOLE; RIFAMPICIN; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; BASAL GANGLION; BRAIN ARTERY; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORPUS CALLOSUM; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE MODEL; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG RESPONSE; FUNGUS CULTURE; HEMIPARESIS; HEMISPHERE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INFECTION RISK; LABORATORY DIAGNOSIS; MENTAL DISEASE; NEPHROTOXICITY; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROSURGERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEIZURE; SYMPTOM;

ANIMALS; ANTIFUNGAL AGENTS; DISEASE MODELS, ANIMAL; HUMANS; NEUROASPERGILLOSIS;

EID: 34547232300     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721080-00004     Document Type: Review

References (101)

1. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005; 366: 1013-25
2. Kleinschmidt-DeMasters BK. Central nervous system aspergillosis: a 20-year retrospective series. Hum Pathol 2002; 33: 116-24
3. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis with voriconazole treatment. Blood 2005 Oct 15; 106 (8): 2641-5
4. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001 Feb 1; 32 (3): 358-66
5. Maschke M, Dietrich U, Prumbaum M, et al. Opportunistic CNS infection after bone marrow transplantation. Bone Marrow Transplant 1999; 23: 1167-76
6. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-15
7. Marr KA, Patterson T, Denning D. Aspergillosis: pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002; 16: 875-94
8. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by aspergillus. Clin Infect Dis 2000; 30: 696-709
9. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine 2000 Jul; 79 (4): 250-60
10. Walsh TJ, Hier DB, Caplan LR. Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients. Ann Neurol 1985; 18: 574-82
11. Donhuijsen K, Pfaffenbach B, Samandari S, et al. Autopsy results of deep-seated mycosis occurring with haematologic neoplasia (1053 patients). Mykosen 1991; 34 Suppl.: 25-7
12. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99-109
13. Yamazaki T, Kume H, Murase S, et al. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999; 37: 1732-8
14. Kume H, Yamazaki T, Abe M, et al. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathol Int 2003 Nov; 53 (11): 744-50
15. Hori A, Kami M, Kishi Y, et al. Clinical significance of extrapulmonary involvement of invasive aspergillosis: a retrospective autopsy-based study of 107 patients. J Hosp Infect 2002 Mar; 50 (3): 175-82
16. Pagano L, Ricci P, Montillo M, et al. Localization of aspergillosis to the central nervous system among patients with acute leukemia: report of 14 cases. Gruppo Italiano Malattie Ematologiche dell'Adulto Infection Program. Clin Infect Dis 1996; 23: 628-30
17. Jantunen E, Volin L, Salonen O, et al. Central nervous system aspergillosis in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2003; 31: 191-6
18. Hagensee ME, Bauwens JE, Kjos B, et al. Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984-1992. Clin Infect Dis 1994; 19: 402-8
19. Wald A, Leisenring W, van Burik JA, et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-66
20. Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322-30
21. Walsh TJ, Hier DB, Caplan LR. Fungal infections of the central nervous system: comparative analysis of risk factors and clinical signs in 57 patients. Neurology 1985; 35: 1654-7
22. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005 Jan; 18 (1): 44-69
23. Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis 2003 Mar; 3 (3): 156-61
24. Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003 Jan 1; 36 (1): 46-52
25. Mylonakis E, Paliou M, Sax PE, et al. Central nervous system aspergillosis in patients with human immunodeficiency virus infection: report of 6 cases and review. Medicine (Baltimore) 2000 Jul; 79 (4): 269-80
26. Guermazi A, Gluckman E, Tabti B, et al. Invasive central nervous system aspergillosis in bone marrow transplantation recipients: an overview. Eur Radiol 2003; 13: 377-88
27. Torre-Cisneros J, Lopez OL, Kusne S, et al. CNS aspergillosis in organ transplantation: a clinicopathological study. J Neurol Neurosurg Psychiatry 1993; 56: 188-93
28. Shuper A, Levitsky KI, Cornblath DR. Early invasive CNS aspergillosis: an easily missed diagnosis. Neuroradiology 1991; 33: 183-5
29. Coley SC, Jager HR, Szydlo RM, et al. CT and MRI manifestations of central nervous system infection following allogeneic bone marrow transplantation. Clin Radiol 1999; 54: 390-7
30. Okafuji T, Yabuuchi H, Nagatoshi Y, et al. CT and MR findings of brain aspergillosis. Comput Med Imaging Graph 2003; 27: 489-92
31. Boes B, Bashir R, Boes C, et al. Central nervous system aspergillosis: analysis of 26 patients. J Neuroimaging 1994; 4: 123-9
32. Murthy JM, Sundaram C, Prasad VS, et al. Aspergillosis of central nervous system: a study of 21 patients seen in a university hospital in south India. J Assoc Physicians India 2000; 48: 677-81
33. Siddiqui AA, Shah AA, Bashir SH. Craniocerebral aspergillosis of sinonasal origin in immunocompetent patients: clinical spectrum and outcome in 25 cases. Neurosurgery 2004; 55: 602-11, discussion 611-3
34. Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 1994 Sep; 140 (Pt 9): 2475-9
35. Berenguer J, Allende MC, Lee JW, et al. Pathogenesis of pulmonary aspergillosis: granulocytopenia versus cyclosporine and methylprednisolone- induced immunosuppression. Am J Respir Crit Care Med 1995; 152: 1079-86
36. Balloy V, Huerre M, Latge JP, et al. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005 Jan; 73 (1): 494-503
37. Verweij PE, Brinkman K, Kremer HPH, et al. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol 1999; 37: 1186-9
38. Kami M, Ogawa S, Kanda Y, et al. Early diagnosis of central nervous system aspergillosis using polymerase chain reaction, latex agglutination test, and enzyme-linked immunosorbent assay. Br J Haematol 1999; 106: 536-7
39. Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 2002; 40: 1496-9
40. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349-57
41. Cox J, Murtagh FR, Wilfong A, et al. Cerebral aspergillosis: MR imaging and histopathologic correlation. Am J Neuroradiol 1992; 13: 1489-92
42. Yuh WT, Nguyen HD, Gao F, et al. Brain parenchymal infection in bone marrow transplantation patients: CT and MR findings. Am J Roentgenol 1994 Feb; 162 (2): 425-30
43. Miaux Y, Ribaud P, Williams M, et al. MR of cerebral aspergillosis in patients who have had bone marrow transplantation. Am J Neuroradiol 1995 Mar; 16 (3): 555-62
44. DeLone DR, Goldstein RA, Petermann G, et al. Disseminated aspergillosis involving the brain: distribution and imaging characteristics. Am J Neuroradiol 1999 Oct; 20 (9): 1597-604
45. Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. Am J Roentgenol 1994; 162: 155-9
46. Dietrich U, Hettmann M, Maschke M, et al. Cerebral aspergillosis: comparison of radiological and neuropathologic findings in patients with bone marrow transplantation. Eur Radiol 2001; 11: 1242-9
47. Offiah CE, Turnbull IW. The imaging appearances of intracranial CNS infections in adult HIV and AIDS patients. Clin Radiol 2006; 61 (5): 393-401
48. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 710-8
49. van Burik JA, Hackman RC, Nadeem SQ, et al. Nocardiosis after bone marrow transplantation: a retrospective study. Clin Infect Dis 1997; 24: 1154-60
50. Goodman JS, Kaufman L, Koenig MG. Diagnosis of cryptococcal meningitis. N Engl J Med 1971; 285: 434-6
51. Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995; 20: 611-6
52. Sanchez-Portocarrero J, Perez-Cecilia E, Corral O, et al. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis 2000 Jul; 37 (3): 169-79
53. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases [published erratum appears in Rev Infect Dis 1991 Mar-Apr; 13 (2): 345]. Rev Infect Dis 1990; 12: 1147-201
54. Patterson TF, George D, Ingersoll R, et al. Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis. Antimicrob Agents Chemother 1991; 35: 1985-8
55. Andriole VT, Miniter P, George D, et al. Animal models: usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. Clin Infect Dis 1992; 14 Suppl. 1: S134-8
56. Roberts J, Schock K, Marino S, et al. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 3381-8
57. Troke PF, Andrews RJ, Marriott MS, et al. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. J Antimicrob Chemother 1987 May; 19 (5): 663-70
58. Chiller TM, Luque JC, Sobel RA, et al. Development of a murine model of cerebral aspergillosis. J Infect Dis 2002; 186: 574-7
59. Chiller TM, Sobel RA, Luque JC, et al. Efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection. Antimicrob Agents Chemother 2003; 47: 813-5
60. Clemons KV, Espiritu M, Parmar R, et al. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49: 4867-75
61. Kirkpatrick WR, Perea S, Coco BJ, et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564-8
62. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37 Suppl. 3: S188-224
63. Boon AP, Adams DH, Buckels J, et al. Cerebral aspergillosis in liver transplantation. J Clin Pathol 1990; 43: 114-8
64. Baddley JW, Stroud TP, Salzman D, et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-24
65. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001 Mar 1; 32 (5): 686-93
66. Harbarth S, Pestotnik SL, Lloyd JF, et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001 Nov; 111 (7): 528-34
67. Ehrmann S, Bastides F, Gissot V, et al. Cerebral aspergillosis in the critically ill: two cases of successful medical treatment. Intensive Care Med 2005 May; 31 (5): 738-42
68. Saulsbury FT. Successful treatment of aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease. Clin Infect Dis 2001; 32: E137-9
69. Darras-Joly C, Veber B, Bedos JP, et al. Nosocomial cerebral aspergillosis: a report of 3 cases. Scand J Infect Dis 1996; 28: 317-9
70. Kerkmann ML, Blaschke-Hellmessen R, Mikulin HD. Successful treatment of cerebral aspergillosis by stereotactic operation and antifungal therapy. Mycoses 1994; 37: 123-6
71. Imai T, Yamamoto T, Tanaka S, et al. Successful treatment of cerebral aspergillosis with a high oral dose of itraconazole after excisional surgery. Intern Med 1999 Oct; 38 (10): 829-32
72. Sanchez C, Mauri E, Dalmau D, et al. Treatment of cerebral aspergillosis with itraconazole: do high doses improve the prognosis? Clin Infect Dis 1995; 21: 1485-7
73. Coleman JM, Hogg GG, Rosenfeld JV, et al. Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery: case report and review of the literature. Neurosurgery 1995; 36: 858-63
74. Camarata PJ, Dunn DL, Farney AC, et al. Continual intracavitary administration of amphotericin B as an adjunct in the treatment of aspergillus brain abscess: case report and review of the literature. Neurosurgery 1992; 31: 575-9
75. Goodman ML, Coffey RJ. Stereotactic drainage of aspergillus brain abscess with long-term survival: case report and review. Neurosurgery 1989; 24: 94-6
76. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135-44
77. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-96
78. Kaiser L, Huguenin T, Lew PD, et al. Invasive aspergillosis: clinical features of 35 proven cases at a single institution. Medicine (Baltimore) 1998; 77: 188-94
79. de Lastours V, Lefort A, Zappa M, et al. Two cases of cerebral aspergillosis successfully treated with voriconazole. Eur J Clin Microbiol Infect Dis 2003; 22: 297-9
80. Tattevin P, Bruneel F, Lellouche F, et al. Successful treatment of brain aspergillosis with voriconazole. Clin Microbiol Infect 2004 Oct; 10 (10): 928-31
81. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005 Oct; 56 (4): 745-55
82. Machetti M, Zotti M, Veroni L, et al. Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis 2000; 2: 140-4
83. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44: 343-501
84. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89
85. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32 Suppl. 1: 67-87
86. Collette N, Van der Auwera P, Lopez AP, et al. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother 1989; 33: 362-8
87. Collette N, Van der Auwera P, Meunier F, et al. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother 1991 Apr; 27 (4): 535-48
88. Coukell AJ, Brogden RN. Liposomal amphotericin B. Drugs 1998; 55: 585-612
89. Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr Opin Investig Drugs 2003 Feb; 4 (2): 179-85
90. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000 Jul; 182 (1): 274-82
91. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996 May; 22 Suppl. 2: S133-44
92. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003 Sep 1; 37 (5): 728-32
93. Kofla G, Ruhnke M. Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opin Pharmacother 2005; 6: 1215-9
94. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445-57
95. Jarvis B, Figgitt DP, Scott LJ. Micafungin. Drugs 2004; 64: 969-82
96. Raasch RH. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev Anti Infect Ther 2004 Aug; 2 (4): 499-508
97. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15
98. Marbello L, Nosari A, Carrafiello G, et al. Successful treatment with voriconazole of cerebral aspergillosis in an hematologic patient [letter]. Haematologica 2003; 88 (3): ECR05
99. Damaj G, Ivanov V, Le Brigand B, et al. Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient. Ann Hematol 2004; 83: 390-3
100. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004 Sep 15; 39 (6): 797-802
101. Elgamal EA, Murshid WR. Intracavitary administration of amphotericin B in the treatment of cerebral aspergillosis in a non immune-compromised patient: case report and review of the literature. Br J Neurosurg 2000 Apr; 14 (2): 137-41